These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 26789870)

  • 1. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
    Alarid-Escudero F; Schrag D; Kuntz KM
    Value Health; 2022 Mar; 25(3):409-418. PubMed ID: 35227453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
    den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
    Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Subgroups among Patients with Stage II Colon Cancer.
    Boland CR; Goel A
    N Engl J Med; 2016 Jan; 374(3):277-8. PubMed ID: 26789877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of chemotherapy benefit for colon cancers.
    Gilbert JA
    Lancet Oncol; 2016 Mar; 17(3):e91. PubMed ID: 26831289
    [No Abstract]   [Full Text] [Related]  

  • 10. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
    Hestetun KE; Aasebø K; Rosenlund NB; Müller Y; Dahl O; Myklebust MP
    Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
    J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
    Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
    Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
    Ma C; Olevian D; Miller C; Herbst C; Jayachandran P; Kozak MM; Chang DT; Pai RK
    Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
    Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
    J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of elastic laminal invasion in colon cancer: elastic laminal invasion-positive stage II colon cancer is a high-risk equivalent to stage III.
    Yokota M; Kojima M; Nomura S; Nishizawa Y; Kobayashi A; Ito M; Ochiai A; Saito N
    Dis Colon Rectum; 2014 Jul; 57(7):830-8. PubMed ID: 24901683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
    Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
    Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts.
    Hansen TF; Kjær-Frifeldt S; Eriksen AC; Lindebjerg J; Jensen LH; Sørensen FB; Jakobsen A
    Br J Cancer; 2018 Nov; 119(11):1367-1373. PubMed ID: 30425348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
    Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
    Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.